MONTVALE, NJ–(Marketwire – September 13, 2010) –  SRS, the leading provider of productivity-enhancing technology and services for high-performance physician specialty practices, today announced a partnership with Medstrat, the pioneer of orthopaedic PACS (digital x-ray) software. SRS will offer its clients an exceptional and innovative PACS system that is fully integrated with the SRS Hybrid EMR and the SRS CareTracker PM.

Capitalizing on its OpenPath™ technology, SRS will incorporate the PACS system so that clients access images directly from within the EMR. The product will be branded as the SRS PACS, powered by Medstrat, and will be implemented, supported, and serviced by SRS.

“PACS is another component of the SRS Unified Desktop that is essential for speed and productivity, and is particularly critical for orthopaedic surgeons,” says SRSsoft CEO Evan Steele. “We researched many PACS companies and selected Medstrat based on its dedication to orthopaedics and our shared commitment to customer service as the highest priority.”

“We are delighted to be working with the leading provider of EMR solutions for the orthopaedics community,” says Michael Cowden, Founder and CEO, Medstrat. “We look forward to jointly helping physicians provide the highest quality care and service to their patients in the most efficient manner.”

Michael Goebel, M.D., physician at Blue Ridge Bone & Joint Clinic in Asheville, NC, has been a successful user of both the SRS Hybrid EMR and Medstrat’s PACS system. “We are delighted that our two primary software vendors have formed this agreement to integrate their systems. Having a single product interface and support network through SRS is a big plus for us.”

About SRS

SRS is the recognized leader in productivity-enhancing EMR technology and services for high-performance orthopaedic practices — with the largest national network of orthopaedists successfully using an EMR. Its key products, the robust SRS Hybrid EMR and SRS CareTracker PM, offer powerful and flexible solutions that streamline clinical workflows and enhance patient care. SRS increases speed, frees physicians’ time, boosts revenue, and heightens patient satisfaction. Prominent orthopaedic groups overwhelmingly choose SRS because of its unique fit with the demands of their specialty. For more information on SRS, visit www.srssoft.com, e-mail [email protected], fax 201.802.1301, or call 800.288.8369.

About Medstrat
Medstrat originated digital x-ray imaging for orthopedic practices to meet the unique needs of the orthopedic surgeon and address the demanding challenges orthopedic surgeons face every day, including the pressure to reduce costs and deliver faster, higher-quality patient care. Based upon a proven, high-performing digital medical imaging platform, Medstrat allows for the elimination of film, chemicals, and processing, increases workflow efficiency and staff productivity, and provides significant cost savings. For more information, call 800-882-4224 or visit www.medstrat.com.

IRVING, TX–(Marketwire – September 13, 2010) –  VHA Inc., the national health care network, announced today that it will offer a new leadership award to honor not-for-profit member hospitals that are leading the way in developing and implementing outstanding sustainability programs. 

“Most hospitals in the U.S. are intensely focused on the care they deliver to patients but not always as focused on the impact they have on the environment,” said Michael Regier, senior vice president of legal and corporate affairs at VHA. “However, due to heightened awareness and commitment to the global and local communities, a growing number of hospital leaders are looking at their organization’s environmental impact and they are doing some pretty amazing things about it. VHA plans to honor those leading hospitals and encourage others to step up.”

VHA will recognize hospitals that have:

• Shown a commitment to the development, implementation and promotion of a sustainability strategy
• Developed a “best in class” sustainability program, such as on-site programs to save energy, recycle, reduce waste or conserve water
• Measured and reported progress toward sustainability goals
• Demonstrated a commitment to increasing awareness of its sustainability story in the community and/or among its employees

The Sustainability Excellence Award is part of VHA’s existing Leadership Award series that honors hospitals for excellence in supply chain management, clinical care and community benefit leadership. The new award is also part of VHA’s larger commitment to recognizing and advancing innovative sustainability initiatives through its own Corporate Citizenship & Sustainability program. 

“VHA, Novation and Provista have taken significant steps that not only support our mission but also make a positive impact on our employees, our member health care organizations and the community around us,” said Terri Scannell, VHA’s director of corporate citizenship and sustainability. “We’re proud that VHA’s own CC&S program has twice received national recognition, and we are excited to introduce the VHA Sustainability Excellence Award that will recognize and applaud our members’ efforts and great work.”

The Sustainability Excellence award program is open to VHA hospitals that were active members in 2010 and that have developed organizational sustainability programs and initiatives. To enter, visit VHA’s Web site and download the Sustainability Excellence Award overview, criteria and application materials. Awards will be given in two categories — one for large IDNS and one for hospitals, and winners will be recognized at the 2011 Leadership Conference in San Diego. 

About VHA — VHA Inc., based in Irving, Texas, is a national network of not-for-profit health care organizations that work together to drive maximum savings in the supply chain arena, set new levels of clinical performance and identify and implement best practices to improve operational efficiency and clinical outcomes. Formed in 1977, through its 16 regional offices, VHA serves 1,400 hospitals and more than 30,000 non-acute care providers nationwide. VHA was ranked by Modern Healthcare as the 7th best place to work in health care in 2009. 

VANCOUVER, BRITISH COLUMBIA–(Marketwire – Sept. 13, 2010) – GrowthPoint Capital Corp. (“GrowthPoint”) is updating its reporting of security holdings in Vigil Health Solutions Inc. (“Vigil”), as a result of the one for twenty consolidation of the common shares of Vigil effective at the opening of trading on September 10, 2010.

As announced by GrowthPoint on August 17, 2010, pursuant to a private agreement, it acquired ownership on July 27, 2010 of $100,000 in debt of Vigil. Post-consolidation this $100,000 is now convertible into, 500,000 common shares of Vigil at a conversion price of $0.20 per common share, representing approximately 10.0% of Vigil’s post-consolidation common shares.

In addition to this $100,000 in convertible debt following Vigil’s share consolidation (and the expiry of 288,000 options prior to the consolidation) GrowthPoint and its affiliates also hold 496,450 common shares representing approximately 9.9% of Vigil’s post-consolidation common shares; 32,500 Deferred Stock Units representing approximately 0.7% of Vigil’s post-consolidation common shares; and 22,800 Stock Options representing approximately 0.5% of Vigil’s post-consolidation common shares. In aggregate, assuming the full exercise and conversion of the aforementioned securities, GrowthPoint and its affiliates would hold approximately 21.0% of the issued and post-consolidation common shares of Vigil.

In addition to owning or exercising control over the Vigil securities through GrowthPoint Capital Corp., GrowthPoint acts jointly or in concert with Greg Peet and GrowthPoint Ventures (VCC) Corp.

GrowthPoint acquired these securities for investment purposes. GrowthPoint may, depending on market conditions and other factors as well as applicable securities laws, acquire additional securities of Vigil through the facilities of the TSX Venture Exchange, private agreements or otherwise. GrowthPoint may, depending on market conditions, sell any or all of its common shares of Vigil.

For additional information, or for a copy of the early warning report filed in respect of the above transaction, please please see contact information below.

ROCKVILLE, MD and SEOUL, KOREA–(Marketwire – September 13, 2010) –  Seegene today announced its successful initial public offering on the KOSDAQ (Korea Securities Dealers Automated Quotations). The company sold 636,500 shares for USD 26.16 (WON 30,500) each, raising USD 16.6 million and giving Seegene a market capitalization of USD 167 million. The company plans to invest the fresh capital in expanding its international market presence, with an emphasis on United States and Japan, where it is seeking regulatory approval for its portfolio of multiplex diagnostic PCR tests.

“This is an exciting day for Seegene, and marks a significant step toward our goal of being a leading global player in the molecular diagnostic industry,” said Jong-Yoon Chun, Chief Executive Officer of Seegene. “The capital that we raised will support the growing demand for our powerful multiplex diagnostic tests.”

Since 2007 Seegene has been growing sales at annualized growth rate of 170 percent. This rapid growth rate continues with sales of USD 9.5 million in the first half of 2010, compared to total 2009 sales of USD 11.2 million.

“Our products are defining a new category molecular diagnostics that are capable of simultaneously detecting multiple pathogens or genetic mutations in a single test. Using Seegene’s products, medical professionals are able to improve patient care by making accurate diagnoses faster, and more cost-effectively.”

The effectiveness of Seegene’s diagnostic testing technology was shown in the 2009 pandemic outbreak of (H1N1). While many molecular diagnostic firms responded to this flu outbreak by introducing individual kits that separately tested for each variant of Influenza A (H1, H3 , H5, and new H1N1), Seegene delivered a multiplex PCR test that simultaneously detected each flu subtype as well as the new H1N1 strain. Furthermore, the Seegene PCR test detected these strains with higher accuracy, specificity and sensitivity.

In July of this year at the AACC Clinical Lab Expo in Los Angeles, CA, Seegene introduced other multiplex molecular diagnostic tests — Magicplex™ and Anyplex™ — based on the company’s powerful READ™ (Real Amplicon Detection) technology:

Magicplex Sepsis, a multi-pathogen screening test that quickly and accurately identifies over 90 leading sepsis-causing pathogens, and Anyplex MDR-TB, a test that identifies Tuberculosis (TB) and genetic mutations causing TB resistance to the drugs isoniazid and rifampicin.

Chun added, “The market response to our READ technology and our new line of Magicplex and Anyplex tests has been extremely positive. We are in discussions with over 20 companies who are interested in licensing the technology or distributing these products in markets worldwide.”

“Later this year Seegene plans to introduce new Magicplex blood-screening and tumor detection tests, as well as a complete automated testing system. As we continue to grow our worldwide market presence, we will seek a NASDAQ listing after approximately three years,” he concluded.

About Seegene

Seegene, Inc. is a leading molecular diagnostics company developing, manufacturing and marketing innovative “multiplex” (or “multi-pathogen detection”) molecular diagnostic products and services. It holds proprietary technologies of both PCR and Real-time PCR named ACP™, DPO™, and READ™, which sets a standard in high-throughput and simultaneous multi-pathogen detection called “multiplex PCR.” The novel multiplex Real-time PCR technology, READ™, overcomes the limitations of conventional Real-time PCR, providing dramatic improvement in sensitivity and specificity. Seegene holds three novel Molecular diagnostic platforms: Seeplex® system adapting DPO™ Technology, Anyplex® and Magicplex® system which are Real-time PCR detection platform adapting DPO™ and READ™ Technology. Seegene’s products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene’s mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology using innovative proprietary technologies.

For more information please visit www.seegene.com or call +301-762-9066.

SANTA ANA, CA–(Marketwire – September 13, 2010) –  SixLog Corporation, an Astro Pak company providing on-site room disinfection and sterilization services, today announced it will showcase its revolutionary iHP™ (ionized Hydrogen Peroxide) technology at the American Society for Healthcare Environmental Services (ASHES) annual conference from September 27-28 at booth #536 at the Gaylord National Resort in National Harbor, Maryland.

SixLog provides room disinfection and sterilization services using its patented misting system to effectively eradicate microorganisms such as Clostridium difficile (C. diff), Vancomycin-resistant enterococcus (VRE), Methicillin-resistant Staphylococcus aureus (MRSA), Acinetobacter and other multi drug-resistant organisms (MDROs). This spore-killing iHP™ system is the next-generation of hydrogen peroxide fogging systems that successfully eliminates pathogens from all environmental surfaces and is faster and more cost effective than alternatives. SixLog’s room disinfection and sterilization services can easily augment hospitals’ terminal cleaning protocol and place current practices at the cutting edge of infection control. 

“I am excited to attend ASHES and demonstrate our new room sterilization technology,” says Vanessa Valdez, general manager of SixLog. “Environmental services (ES) departments across the nation are looking for innovative solutions to eradicate the growth of infection-producing organisms. SixLog’s iHP™ room sterilization technology enables ES professionals to quickly and effectively deploy a service that will have a fast impact on reducing the number of HAIs. We offer fully integrated and customized solutions for preventative room sterilization and/or outbreak control.”

In addition the proven efficacy of iHP™, it is also compatible with patient support equipment, including sensitive electronics, as it is noncorrosive. iHP™ leaves no residue behind, and upon completion, breaks down into just water and oxygen making it safe for staff, patients and visitors as well as the environment. A few examples of iHP™ room disinfection/sterilization applications include:

• Emergency and patient rooms
• Isolation rooms
• Intensive care units
• Surgical suites
• Tissue culture labs
• Bone marrow transplant suites
• Blood banks
• Sputum induction areas

For more information about SixLog’s iHP™ technology or to view it in action, please visit SixLog at booth #536 at ASHES 2010 during September 27-28 at the Gaylord National Resort in National Harbor, Maryland, or contact us at [email protected] or 877-4SIXLOG (474-9564).

About SixLog Corporation
SixLog provides on-site biological decontamination for equipment, rooms, entire buildings, and modes of transportation such as ambulances, trains, and cruise ships. Its proprietary iHP™ (ionized Hydrogen Peroxide) decontamination technology is utilized across a variety of industries including Life Sciences, Pharmaceutical, Healthcare, First Responders, Transportation, and Public Facilities. SixLog is privately held with headquarters in Santa Ana, CA. For more information, please visit www.sixlog.com.

Click here to see all recent news from this company

PEARL RIVER, NY–(Marketwire – September 13, 2010) –  Sanford “Sandy” Elsass, President of Uni-Ter Underwriting Management Corporation (UUMC), has been elected a Director of U.S. RE Companies, Inc., an international financial services and reinsurance brokerage firm, Tal P. Piccione, Chairman and Chief Executive Officer, announced.

UUMC is a subsidiary of U.S. RE Companies that builds and manages Risk Retention Groups in the healthcare industry. The RRGs provide general and professional liability insurance to long-term care facilities, physicians/surgeons, nurses, other healthcare professionals, and related businesses in 48 states. Elsass joined the U.S. RE Group in 2002. He also serves as a senior officer of U.S. RE.

“Sandy Elsass has built Uni-Ter into a major profit center. His rich experience in brokerage management and investment banking will be invaluable to our Board as U.S. RE grows,” Piccione said.

Elsass has been in the insurance industry and related business for 30 years. He serves currently as a Director of the Nevada Captive Insurance Association, the National Risk Retention Association, and Sunshine State Insurance Company of Florida. Prior to joining U.S. RE, he was an investment banker with Marsh Berry and Company. Earlier, he was President of Montgomery & Collins, a wholesale insurance broker that was sold to Marsh & McLennan. Elsass is a former Director of Wainwright Bank & Trust Company, Boston. He is a graduate of Ohio University.

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – September 13, 2010) –  FDAAdvisoryCommittee.com (FDAAC.com), a provider of live video webcasts of Food and Drug Administration (FDA) Advisory Committee meetings, today announced that it will webcast the Endocrinologic and Metabolic Drugs Advisory Committee’s discussions on the cardiovascular implications for Meridia® as well as the safety and efficacy of Lorqess®. The Meridia meeting is scheduled for September 15, 2010 from 8:00 a.m. ET to 5:00 p.m. ET. The Lorqess meeting will be held on September 16, 2010 from 8:00 a.m. ET to 5:00 pm. ET. 

On September 15, Abbott Laboratories’ new weight loss drug Meridia comes under review as experts discuss the results of clinical trials that evaluated the potential benefits of weight loss with the drug on major cardiovascular adverse events. Meridia acts as an appetite suppressant in combination with a diet and exercise regimen.

The Committee will review the safety and efficacy of Lorqess, Arena Pharmaceuticals’ new diet pill, on September 16. The drug acts as an appetite suppressant and works in conjunction with diet and exercise for obese patients as determined by body mass index (BMI).

Audience members, including biotech equity analysts, pharmaceutical employees, and journalists will be able to watch from anywhere in the world as the Committee reviews Meridia and Lorqess. FDAAC.com will webcast the meeting live and on location from the Inn and Conference Center at the University of Maryland University College.

FDAAC.com is committed to delivering the highest quality of video and experience. By utilizing h.264 encoding in conjunction with Flash Media, FDAAC.com’s webcasts deliver a near instantaneous stream. These high-quality streams can be accessed from anywhere around the globe and are archived for six months after the live event for unlimited review.

FDAAC.com‘s webcasts are powered by TalkPoint, a provider of Web-based audio and video Webcasting solutions and services. With over a decade of experience, TalkPoint has developed the most robust, scalable, interactive webcasting platform in the industry. TalkPoint’s easy-to-use applications incorporate audio, video, slides, and other interactive elements to deliver high-impact webcasts cost-effectively.

To join the webcasts on September 15 and 16 at 8 a.m. ET register at http://fdaac.com

About FDAAdvisoryCommittee.com
FDAAC.com provides live video webcasts of FDA Advisory Committee meetings captured on location. These meetings cover an array of topics related to medicinal health including OTC, prescription and treatment devices. Very often meetings will result in rulings on clinical trials, final approval and bans of medications and treatment options. TalkPoint is the exclusive webcast provider for FDAAdvisoryCommitte.com.

For more information on FDAAC.com, go to www.fdaac.com.

PORT HUENEME, CA–(Marketwire – September 13, 2010) –  (TSX-V: KLH) (PINKSHEETS: SBOTF) — Stellar Biotechnologies, Inc. is collaborating with Bayer Innovation GmbH (BIG) in the development of biopharmaceuticals. Bayer’s personalized idiotype vaccine for the treatment of Non-Hodgkin’s-Lymphoma (NHL) is currently in Phase I clinical trials, and the cooperation is related to the development of a personalized Non-Hodgkin’s-Lymphoma vaccine. The vaccine antigen is produced in tobacco plants based on Bayer’s proprietary magnICON^® technology. Bayer Innovation GmbH is a wholly-owned subsidiary of Bayer AG (PINKSHEETS: BAYRY) (XETRA: BAYGN) (LSE: BYRB).

A critical project feasibility milestone in the “Joint Development Agreement” has been achieved. Under terms of the agreement, Stellar Biotechnologies supplies Keyhole Limpet Hemocyanin (KLH) which is coupled to the idiotype protein produced in tobacco plants. KLH is a highly potent immuno-stimulatory protein, which stimulates the lymphocytes to recognize even familiar proteins attached to it as foreign. During the immune response that ensues, the lymphocytes mainly focus on the peptide sequence of the attached tumor idiotype. This so-called immunogenic carrier molecule comes solely from the rare keyhole limpet, and Stellar has technology for the maintenance of the animal, the non-lethal extraction of the critical molecule and a profitable refinement process of KLH.

By consent of both parties, Stellar will receive a milestone payment from BIG, and the co-development agreement is being expanded and continued to achieve important new endpoints that may prove critical to Bayer’s interest in therapeutic vaccines based on its plant-based protein expression system, the magnICON® technology.

Dr. John Butler, Global Project Leader of Plant Made Pharmaceuticals (PMP) for Bayer, said, “We are happy to have achieved this important milestone, and appreciate working with Stellar’s talented scientific team, led by Professor Daniel Morse. Together with Bayer’s scientists and engineers, we believe we have made a significant impact on the potential cost structure as well as efficiency and sustainability of our vaccine production. Securing a long-term sustainable KLH supply is a key element in our efforts to enable a new therapy that could significantly benefit disease outcomes and quality of life of NHL patients.”

Frank Oakes, CEO of Stellar, said, “Stellar has been honored by the opportunity to partner with the cutting-edge team at Bayer Innovation, and now, to grow this new relationship to the next level. Bayer Innovation is among the highest regarded participants in the PMP field, and we believe the credibility that comes from working with an internationally recognized biotechnology, materials science, and pharmaceutical powerhouse is incalculable. We are excited by the opportunity for growth in this relationship, and the potential for exploring future business development opportunities with Bayer Innovation.”

About Bayer Innovation GmbH (BIG — http://www.bayer-innovation.com/en/homepage.aspx) is part of Bayer’s innovation strategy and complements the innovation activities of the different subgroups in the fields of health care, nutrition and high-quality materials. Its objective is to identify and develop new growth opportunities, preparing entry into new and expanding markets. Currently the focus is on medical technology and the production of plant-made pharmaceuticals.

About Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) (www.StellarBiotechnologies.com) is a world leader in sustainable manufacturing of pharmaceutical grade immune carrier proteins (ICP), particularly with regard to the present most important pharmaceutical protein in this class, KLH (Keyhole Limpet Hemocyanin). This ancient evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source.

Statements in this press release other than purely historical factual information, including statements relating to revenues or profits, or the Company’s future plans and objectives, or expected sales, cash flows, and capital expenditures constitute forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in the Company’s business, including risks inherent in the technology history. There can be no assurance that such forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company’s securities set out herein in the United States, or to, or for the benefit or account of, a U.S. person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

JERICHO, NY–(Marketwire – September 13, 2010) –  SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. (“TRDX” or the “Company”) (PINKSHEETS: TRDX) today announces that it believes that the future looks very bright for itself and its sublicense partner, Montreal-based Genesis Biopharma, Inc., as they continue making progress regarding their new compound in development for the treatment and potential cure of Painful Diabetic Neuropathy (PDN).

According to the International Diabetes Federation the global health expenditure on diabetes is expected to total at least USD 376 billion in 2010 and USD 490 billion in 2030. (http://www.idf.org/webdata/docs/PIIS0168822710000495.pdf)

Back in 2003 the American Diabetes Association estimated that in the U.S. the total annual cost of treating diabetic peripheral neuropathy and its complications was $10.91 billion. (http://care.diabetesjournals.org/content/26/6/1790.full)

ABOUT PDN:

PDN is one of many complications of diabetes. Forty to fifty percent of diabetic patients may develop PDN over 15 to 20 years. PDN is present in 11.6% of patients with Type I diabetes and 32.1% of patients with Type II diabetes. PDN may present itself as a progressive build-up of unpleasant sensory symptoms including tingling (paraesthesia), burning pain, radiating pain down the legs and toes and lancinating or contact pain. The pain is more severe during the night and often prevents sleep. Some patients may be in a constant state of tiredness because of sleep deprivation while others are unable to maintain employment.

1. According to the World Health Organization there are approximately 220 million people worldwide who have diabetes

   (http://www.who.int/mediacentre/factsheets/fs312/en/). In the U.S., according to the 2007 National Diabetes Fact Sheet, a total of 23.6 million had diabetes of which 17.9 million were already diagnosed and the rest, 24%, were undiagnosed.

   (http://www.diabetes.org/diabetes-basics/diabetes-statistics/). If you add the undiagnosed cases to the 220 million reported by the World Health Organization the total number could exceed 270 million worldwide.

2. Diabetic neuropathy can cause nerve damage in the feet that leads to decrease or loss of sensation. As a result, a blister or a cut can go unnoticed. Any infection that might ensue can result in tissue death (gangrene) and in some cases severe damage can lead to amputation of toe, foot or even leg. Each year about 80,000 – 84,000 amputations are performed in the U.S. alone (See Diabetes-Related Amputation Statistics:
   http://www.isletsofhope.com/diabetes/complications/amputation_1.html#diabetes).

   How many of these amputations could have been avoided had a solution been made available?

Mr. Leo Stella, CEO of Genesis, has stated: “Until now, there is absolutely no mechanism based treatment that can reverse neuropathy associated with diabetes. Drugs exist that have a temporary effect on the pain, but these drugs cannot cure the cause. The goal of Genesis Biopharma is to develop a drug that will cure this terrible condition.”

Dr. Jan Stahl, CEO of TRDX, commented: “The opportunity is very significant for all the stakeholders in this PDN solution. We will continue our efforts to make this potential cure a reality and deliver quality value for our shareholders.”

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. (www.genesisbiopharma.com) is a Canadian corporation founded in 2007 to exploit the commercial potential for the therapeutic use of peptidomimetic (modified amino acid peptides) compounds. Amino acids are the building blocks of proteins, which are found in every cell. Proteins consist of extremely long and complex amino acid chains. In contrast, a peptide is a short string of amino acids, joined by chemical bonds (also called “amide bonds”).

About SCIMEDENT f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)

SciMeDent is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.

Cautionary Statement Regarding Forward-Looking Statements

A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the sufficiency of existing capital resources, technological or industry changes and uncertainties related to the development of the Company’s business model. The actual results the Company may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.

JERICHO, NY–(Marketwire – September 10, 2010) –  SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. (“TRDX” or the “Company”) (PINKSHEETS: TRDX) today confirms it has completed the structuring of DiabetRX Pharma Corp. (“DiabetRX”) which will be assigned the Sublicense and upon Final Closing will be 100% owned by TRDX.

In addition, the Company provides the following details regarding the recently executed Definitive Sublicense Agreement (“Definitive”) with Montreal-based Genesis Biopharma, Inc. (“Genesis”).

Dr. Jan Stahl, CEO of TRDX, commented: “Since the signing of the Definitive Agreement, I am very happy with the progress we have made with Genesis. We feel confident in the current steps we are taking to complete the Initial Closing and first Tranche financing. We view DiabetRX as a long term investment with large potential and look forward to the Final Closing.”

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. (www.genesisbiopharma.com) is a Canadian corporation founded in 2007 to exploit the commercial potential for the therapeutic use of peptidomimetic (modified amino acid peptides) compounds. Amino acids are the building blocks of proteins, which are found in every cell. Proteins consist of extremely long and complex amino acid chains. In contrast, a peptide is a short string of amino acids, joined by chemical bonds (also called “amide bonds”).

About SCIMEDENT f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)

SciMeDent is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.

Cautionary Statement Regarding Forward-Looking Statements

A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the sufficiency of existing capital resources, technological or industry changes and uncertainties related to the development of the Company’s business model. The actual results the Company may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.

PT. HUENEME, CA–(Marketwire – September 10, 2010) – Stellar Biotechnologies, Inc. (PINKSHEETS: SBOTF) (TSX-V: KLH) announces filing for patent protection of inventions related to its native Immunogenic (IMG) KLH technology platform and immune status monitoring product portfolio. KLH (keyhole limpet hemocyanin) is presently the most pharmaceutically important ICP (immune carrier protein) and IMG KLH is the most effective immune stimulant for use in cancer, viral and parasite vaccines; animal vaccines; and diagnostic products. Patent claims include pharmaceutical grade compositions of matter, processes for manufacture and methods of use in a wide range of therapies.

John Sundsmo, Ph.D., VP Research and Intellectual Property, said, “With filing of this patent application Stellar has achieved an important milestone on the road to becoming the preeminent world leader in development and manufacture of pharmaceutical grade immune carrier proteins. We are very pleased with the progress achieved by our scientists and what this patent application tangibly demonstrates.”

Corporate Website: www.StellarBiotechnologies.com
Stellar News at Marketwire: http://www.marketwire.com/mw/search.do?params=&grpSearch=C&companyid=70788

About Stellar Biotechnologies, Inc. (PINKSHEETS: SBOTF) (TSX-V: KLH) – (www.StellarBiotechnologies.com): is a world leader in sustainable manufacturing of pharmaceutical grade immune carrier proteins (ICP), particularly with regard to the present most important pharmaceutical protein in this class, KLH (Keyhole Limpet Hemocyanin). This ancient evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company’s securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

TAMPA, FL–(Marketwire – September 10, 2010) –  Sage North America today announced that the Sage Healthcare Division, a leading provider of electronic health records (EHR) and practice management software, has been named a preferred vendor by the Massachusetts eHealth Institute to make available the Sage Intergy Meaningful Use Edition to all of the institute’s thousands of participating healthcare providers.

Massachusetts eHealth Institute is part of an extensive network of 60 Regional Extension Centers (RECs) across North America that serves as a neutral source for EHR and health information technology (HIT) as providers seek to navigate EHR options and select vendors that meet meaningful use requirements. Massachusetts eHealth Institute performed an exhaustive analysis of vendors in the HIT landscape prior to recommending solutions to its physician base.

“We are pleased to have Sage join our select list of certified health IT companies that will help thousands of health care providers across Massachusetts successfully transition to electronic health records,” said Rick Shoup, Ph.D., Director of the Massachusetts eHealth Institute. “Widespread deployment of electronic health records leads to better quality care for patients, reduces health care costs and spurs new jobs in the health care industry.”

Sage Intergy line of products and services met Massachusetts eHealth Institute’s standards for quality. By implementing a fully automated EHR such as Sage Intergy, providers will be better able to achieve meaningful use.

Through the partnership, Sage will support Massachusetts eHealth Institute’s goal to increase quality of care and improve public health.

“Being named a preferred vendor by the Massachusetts eHealth Institute means Sage will continue to provide physicians within the state with IT solutions and support as they move toward meaningful use and into the new healthcare economy,” said Ken Ernsting, Vice President of Business Development for Sage Healthcare Division. “We’re proud to serve medical professionals in Massachusetts, and aligning with this leading health organization.”

Clinics eligible to utilize Massachusetts eHealth Institute’s subsidized services include Priority Primary Care Providers (PPCP) in the area of family medicine, obstetrics, and gynecology, general internal or pediatric medicine. In addition, practices must be either individual or a small group practices (defined as 10 or fewer professionals with prescriptive privileges in the practice) primarily focused on primary care; public and critical access hospitals; and community health centers and rural health clinics.

About Massachusetts eHealth Institute
The Massachusetts eHealth Institute (MeHI), a division of the Massachusetts Technology Collaborative, is the state-designated entity for health care innovation, technology and competitiveness. Established by Governor Patrick and the Massachusetts Legislature in Chapter 305 of the Acts of 2008, MeHI is responsible for advancing the dissemination of health information across the Commonwealth, including the deployment of EHR systems in all healthcare provider settings that are networked through a statewide HIE. For more information on MeHI, go to www.maehi.org. 

About Sage Healthcare Division
Sage Healthcare Division provides integrated electronic health records, EDI applications and practice management systems to approximately 80,000 physicians and thousands of ambulatory care practices throughout North America. These systems enable physicians and practice managers to better manage their practices and improve profitability. Sage Healthcare Division is based in Tampa, Fla., and is a division of Sage North America. For more information, please visit www.sagehealth.com or call (877) 932-6301.

About Sage North America
Sage North America is part of The Sage Group plc, a leading global supplier of business management software and services. Sage North America employs 4,000 people and supports 3.1 million small and midsized business customers, including medical practices in the United States. The Sage Group plc, formed in 1981, was floated on the London Stock Exchange in 1989 and now employs 13,100 people and supports 6.2 million customers worldwide. For more information, please visit the Web site at www.sagenorthamerica.com.

© 2010 Sage Software, Inc. All rights reserved. Sage, the Sage logos, and the Sage product and service names mentioned herein are registered trademarks or trademarks of Sage Software, Inc. or its affiliated entities. All other trademarks are the property of their respective owners.

LOS ANGELES, CA–(Marketwire – September 10, 2010) –  MMRGlobal, Inc. (OTCBB: MMRF) (www.mmrglobal.com) announced today the formal launching of a new department, MMRGlobal Travel and Benefits Sales Group. The group will be headed by Patrice A. Shilling, newly named Vice President, Global Travel and Benefit Sales. Shilling is an experienced travel executive who has worked in senior management positions at Travelocity Business, American Express, Alitalia Airlines and Le Méridien and whose clients have included Samsung, McKesson, Medtronic, Accenture, UBS, Boston Scientific and Liberty Mutual, amongst numerous other Fortune 500 and 1000 companies.

Robert H. Lorsch, MMRGlobal Chairman and CEO, said, “Patrice Shilling will lead an initiative to sell our branded Personal Health Record (PHR) (www.mmrvideos.com) and MyEsafeDepositBox products to travel procurement groups and employers with the emphasis on how they add to the safety and security of employees who travel globally, particularly expats. Our strategy will also include targeting organizations like ADP who work regularly with human resources executives and corporate purchasing departments.”

Shilling said, “Our plan envisions selling through corporate procurement, human resources and risk management, as these are untapped channels. Opportunity exists to establish strategic partnerships and alliances with online technology companies, including associations, financial and affinity groups, reward programs and travel providers such as my previous employers American Express and Travelocity Business.”

About MMRGlobal, Inc.
MMR Global, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMR Global, Inc. and its products, visit www.mymedicalrecords.com and view the videos at www.mmrtheater.com.

Forward-Looking Statements
Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements, and some can be identified by the use of words (and their derivations) such as “need,” “possibility,” “offer,” “development,” “if,” “negotiate,” “when,” “begun,” “believe,” “achieve,” “will,” “estimate,” “expect,” “maintain,” “plan,” and “continue,” or the negative of such terms and other comparable terminology. MMRGlobal, Inc. disclaims any intent or obligation to revise or update any forward-looking statements. These forward-looking statements are based on MMRGlobal, Inc.’s reasonable expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. The information discussed in this release is subject to various risks and uncertainties related to changes in MMRGlobal, Inc.’s business prospects, results of operations or financial condition, government regulation, and such other risks and uncertainties as detailed from time to time in MMRGlobal, Inc.’s public filings with the U.S. Securities and Exchange Commission.

Click here to see all recent news from this company

MADISON, WI–(Marketwire – September 10, 2010) –  TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for cancer care, today announced that CFO Thomas Powell and Vice President of Operations and Business Development Eric Schloesser will present at Baird’s 2010 Health Care Conference on Wednesday, September 15, 2010 at 11:00 a.m. ET. The conference will be held at the St. Regis New York Hotel in New York City, N.Y.

A live audio Webcast of the presentation will be available on the investor relations page of TomoTherapy.com. For those who are unable to listen to the live presentation, an archive of the Webcast will be available on the company’s site for 30 days following the presentation.

About TomoTherapy Incorporated 
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy^® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art^® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD^™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile^™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

MUNDELEIN, IL–(Marketwire – September 9, 2010) –  As part of Medline’s ERASE CAUTI™ program, created to help clinicians reduce the risk of urinary catheter-associated infections, the company today announced the launch of a pediatric catheter tray designed to help clinicians better perform and manage urinary catheterizations for children. The new tray introduces “Buddy the Brave,” a friendly, upbeat animal character, to help younger patients better manage the catheter process. Buddy is featured on the tray’s packaging, in a children’s activity card and on a bravery sticker.

“Our ‘Buddy the Brave’ character and related materials may help children focus their attention away from the procedure, which will help them to tolerate what can be an unpleasant experience,” said Alecia Cooper, senior vice president of clinical services for Medline. “The ERASE CAUTI system combines evidence-based principles and training with a revolutionary-designed tray to assist the clinician in using a proven and safe method for catheter insertion and maintenance.”

In a survey done on 110,709 pediatric ICU patients, 6,290 healthcare-associated infections were noted. The top three major sites of infections, accounting for 64% of all healthcare-associated infections, were bloodstream infections (28%), pneumonia (21%), and urinary tract infection (15%). Each of these infections was strongly associated with use of an invasive device.¹

The new pediatric tray is the latest addition to Medline’s ERASE CAUTI product line. Similar to the adult version, the new pediatric tray features an innovative one-layer design. The one-layer design (versus the industry norm of two layers) supports and encourages a logical “best practices” sequence of events during catheterization that helps the provider adhere to current recommended healthcare practices. The new tray design is intuitive, reduces variance in care process and promotes efficiency.

Other features of the ERASE CAUTI pediatric catheter tray system include:

Clear photography of tray contents. In Medline’s new pediatric Foley catheter tray, the product instructions and clear color images are located on the outside to encourage clinicians to review the information before they start. To help identify the contents of the kit, the label features an actual color photo of the tray components, including a picture of Buddy the Brave that easily identifies the product as a pediatric tray. The photo can also be used to discuss the procedure with the patient and parent. The outer label opens like a book and on the inside is a clear, step-by-step instructional guide to catheter insertion.

Checklist that helps practitioners “do the right thing.” The outer label contains “trigger tools,” according to Cooper, to promote the recommended guidelines from the Centers for Disease Control and Prevention (CDC). A checklist of clinical indications for catheterization is printed on a peel-off sticker. The checklist is formatted to easily fit in the patient chart or medical record. It is also available in an electronic format for electronic documentation.

Buddy the Brave Activity Card and family education resource. To keep young patients distracted from the medical procedure, an activity card is included in the tray. The card includes a story featuring Buddy the Brave, a word find game and a maze. The activity card also provides useful family education on urinary catheters and the catheterization process.

Competency validation tools. A key component to the effectiveness of the ERASE CAUTI program is the cutting edge online competency and measurement tools that assess and sustain staff results. The interactive competency programs are available on Medline University, Medline’s online education resource. They are available to staff anytime and can be easily incorporated into the annual skills competency program for a facility’s nursing staff.

About Medline Industries, Inc.
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended-care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, Ill., Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest-growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and healthcare systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities and on-staff clinicians.

WINCHESTER, CA–(Marketwire – September 9, 2010) –  James Bertalotto of Springdale, Arkansas was the door gunner and crew chief of a Huey helicopter in Vietnam. He served two tours from 1966-1969. “When you’re the crew chief and you are assigned to a helicopter, you go wherever that ‘copter goes. It’s like a cowboy and his horse.” For Bertalotto, that helicopter took him into some life experiences that caused trauma which to this day he still has trouble overcoming. After all these years the Vietnam War still rages within him. “Not all wounds are visible,” said Bertalotto. Still, he tries to cope. He says he receives excellent care at the Fayetteville VA Medical Center where he goes for therapy twice a week. It was during a therapy session that Bertalotto was first introduced to the Help Hospitalized Veterans (HHV) arts & crafts program.

Bertalotto said, “I have a wife of 40 years, two children and five grandchildren and they are the love of my life. I started working on the HHV craft kits about three years ago and really enjoy working on them. I get about three or four a year and work on them with my grandchildren. It’s a special time to share with them… to listen, laugh and share a hug.” Bertalotto recently worked on one of HHV’s newest kits — the Veterans Pride Desktop Flag kit. “We were all so proud of the flags in the kit that I instructed my grandkids to put it on my casket when I pass away,” he added. Bertalotto says working on the craft kits takes his mind away from his troubling thoughts. “The kits bring a level of enjoyment into my life I wouldn’t have otherwise, but the hugs are the best part of working on them. That’s the best medicine of all.”

HHV is the largest supplier of free therapeutic arts & crafts kits to VA and military hospitals worldwide. For more information on HHV products and services, please visit www.hhv.org or call 1-888-567-VETS.

Documents and/or Photos available for this release:

PDF_of_release

To view supporting documents and/or photos, go to www.enr-corp.com/pressroom and enter Release ID: 269831

WEST HARTFORD, CT–(Marketwire – September 9, 2010) –  ORLive, the leader in online medical video, presents a live interactive broadcast focusing on the use of artificial disc treatments for cervical disease. In addition ORLive invites you to take part in the latest installment of the Virtual Brain Tumor Board, and wraps up our back to school focus with three new educational video referrals.

NEW ON ORLIVE

LIVE VIDEO — Artificial Disc Treatments for Cervical Disease
Live Thursday, September 9, at 7:00PM

Until recently, spinal fusion was the surgical solution to cervical disc disease. ORLive invites you to watch footage of an Artificial Discectomy performed by William Kuhn, MD of Halifax Hospital, and join in on a live online discussion with the doctor and patient, Ali Rabatsky. 

Viewers of this video are invited to interact with the team via the ORLive website, where you can also request a reminder to alert you when this video is going live.

ORLIVE REFERRALS – Week of September 5, 2010
Each week ORLive highlights on-demand videos for our membership and visitors. 

Medical Education Referral: Defining and Treating Chronic Pain from Beth Israel Hospital in New York City.

CME Referral: The Science and Medicine of Parkinson’s Disease from CMEducation Resources.

Viewer’s Referral: Landmark Practice Advances in STEMI and ACS from CMEducation Resources.

HIGHLIGHTS

NOW ON-DEMAND — Surgical and Medical Treatments for Type 2 Diabetes
Now Available On-Demand

Type 2 diabetes can lead to potentially deadly complications for many patients, but the team at NewYork-Presbyterian remains on the forefront of research and treatment innovations. Join Dr. Francesco Rubino, Chief, Gastrointestinal Metabolic Surgery at the Weill Cornell Medical Center, Dr. Judith Korner, from Columbia University Medical Center, and Dr. Louis Aronne, from the Weill Cornell Medical Center, as they review the advancements that are being made and see what happens when gastric bypass surgery results in a possible remission of diabetes.

Viewers of this video can still interact with the team via the ORLive website, where you can also request updates as they become available.

FEATURED CHANNEL — Sorin Group
With over 40 years of experience, Sorin Group is responsible for many of the innovations that have made heart valve replacement and repair among the safest and most effective procedures in the world today. ORLive invites you to watch and learn as Sorin presents video of many of these devices on the Sorin ORLive Channel. 

PREVIEW — Continuum® Acetabular System and Zimmer® M/L Taper with Kinectiv® Technology
Premieres Thursday, September 23, 2010 at 7PM EDT

On Thursday, September 23rd at 7PM EDT Zimmer Medical Education will broadcast an ORLive Total Hip Arthroplasty featuring the Continuum Acetabular System and the Kinectiv Modular Neck Technology. The surgery will be performed by Dr. Mark Hartzband, Hartzband Center for Hip and Knee Replacement, L.L.C., Paramus, NJ and will be moderated by Dr. Paul Duwelius, St. Vincent Hospital, Portland, OR. The broadcast will last one hour and will show the entire surgical procedure. Following the live broadcast the surgery will be archived for future playback.

This opportunity allows for firsthand insight of the safe and effective implantation and surgical procedure involved with the Continuum® Acetabular System and the Zimmer® M/L Taper with Kinectiv® Technology.

This surgery video is available exclusively to members of the ORLive community, and members can interact and ask questions via the ORLive website. Learn more about this broadcast or get a reminder at ORLive.com, and be ready to view this exciting procedure by activating your free membership to ORLive today.

About ORLive
ORLive is the leading provider of video communication channels to the healthcare community. Working collaboratively with hospitals and device manufacturers, ORLive produces and distributes customized, interactive, video programs that demonstrate the latest advances in medicine, surgical techniques and product innovations. The ORLive broadcasting network provides an intimate look at over 650 live and on-demand surgeries to a global audience, streaming over 50,000 hours of programming each month. The ORLive network can be found on-line at www.ORLive.com.

id=”nav_links”>

VICTORIA, BRITISH COLUMBIA–(Marketwire – Sept. 9, 2010) – Vigil Health Solutions Inc. (“Vigil”) (TSX VENTURE:VGL)today announced that, effective the opening of trading on September 10, 2010, Vigil’s common shares will be consolidated on the basis of one post-consolidation common share for each twenty pre-consolidation common shares. The consolidation was approved at Vigil’s Annual General and Special Meeting of shareholders held on August 24, 2010. Vigil currently has 100,046,135 pre-consolidation common shares outstanding. Vigil will have approximately 5,002,310 post-consolidation common shares outstanding. Vigil’s name and trading symbol on the TSX Venture Exchange will not be changed in connection with the consolidation.

KYLE, TX–(Marketwire – September 9, 2010) –  CommuniCare Health Centers, a Federally Qualified Health Center that provides health care in Bexar and Hays Counties, announced today that it has received a $56,533 grant from the Austin Affiliate of Susan G. Komen for the Cure®. The grant will provide low-income, uninsured women in Hays County with greatly needed educational information about breast cancer, access to clinical breast exams, and mammograms.

“We are so pleased to receive the grant from the Austin Affiliate of Susan G. Komen for the Cure® and look forward to making breast health services available to more women in Hays County,” said Debbora A. Thompson, Chief Executive Officer of CommuniCare Health Centers. “Without organizations like the Komen Foundation many low-income, minority, uninsured women would not have access to critical breast health screenings.”

The services provided by the grant will be offered to uninsured women aged 40 to 64 at CommuniCare’s health center at 1340 Wonder World Drive in San Marcos and at its new health center in Kyle, CommuniCare Health Centers – Kyle at 2810 Dacy Lane. To access services funded by this grant, please call 512.392.1718. CommuniCare will be opening CCHC-Kyle, on September 20, 2010 where medical, dental and behavioral health care will be available to area residents. 

About the Austin Affiliate of Susan G. Komen for the Cure:
The Austin Affiliate of Susan G. Komen for the Cure® has been working to better the lives of those facing breast cancer in the Greater Austin community since 1999. Through events such as the Komen Austin Race for the Cure® and other philanthropic endeavors, the Austin Affiliate has invested nearly $7 Million in community breast health programs in Bastrop, Caldwell, Hays, Travis, and Williamson Counties. The Affiliate makes grants to local hospitals and community organizations that provide breast health education and breast cancer screening and treatment programs for medically underserved women.
For more information on the Austin Affiliate of Susan G. Komen for the Cure® please visit www.komenaustin.org.

About CommuniCare:
CommuniCare Health Centers (CCHC) has served San Antonio for over 38 years. CCHC provides medical, dental and behavioral health services to uninsured and underserved residents in Bexar and Hays counties and delivered more than 151,000 visits in 2009 in two health centers in San Antonio and one in San Marcos. As a non-profit community health center, it serves those with Medicaid, Medicare, medical insurance and those that do not have insurance, charging on a sliding-fee scale based on annual household income and family size. For more information on Barrio Comprehensive Family Health Care Center, Inc. dba CommuniCare Health Centers please visit www.communicaretx.org.

DENVER, CO–(Marketwire – September 9, 2010) –  The Breakaway Group will host an exclusive group of healthcare leaders, educators and innovators at the Inverness Hotel & Conference Center in Denver, from September 23-25, for the 2010 Healthcare Forum: Beyond Implementation, The New Leadership Agenda for Lasting EMR Adoption. Featuring a presentation by Wil Yu, Special Assistant, Innovations and Research, Strategic Health IT Advanced Research Projects, Office of the National Coordinator for Health IT, the central theme of the forum centers on the changing leadership agenda for three roles in healthcare: the CEO, CIO and Clinical Leadership.

Attendees and presenters include top leaders from Trinity Health, UT Medical Group, Arkansas Children’s Hospital, Baptist Health System and Hartford Health Care, and others. The 2010 Healthcare Forum continues the conversation launched in 2007 at the Healthcare Summit in Vail, Colo., where discussion focused on the challenge of how to treat an HIT implementation as more than a single event. 

“The Healthcare Forum provides a way for C-level executives to collaborate on finding successful ways to shift leadership priorities, to refocus organization efforts around EMR adoption,” said Charles Fred, chief executive officer of The Breakaway Group. “We are excited to offer the results of our research as a way to facilitate meaningful use and sustainable EMR adoption in the healthcare industry.” 

Recent Research Serves as Foundation for New Leadership Agenda
In the face of increased pressure to adopt new technology, healthcare executives have been led to reprioritize their everyday roles. Recent in-depth research from The Breakaway Group into the major barriers of EMR adoption and improved clinical outcomes (Beyond Implementation: A Prescription for Lasting EMR Adoption, 2010, Haugen, H., Woodside, J.) will serve as a foundation for the leadership agenda discussion. 

The authors, Dr. Heather Haugen and Dr. Jeffrey Woodside, M.D., conducted more than 18 months of research with leaders and healthcare organizations representing more than 3,200 physicians and 350 ambulatory sites. Through case studies and research, they examine why the transition to EMR is often overly costly, lengthy and frustrating.

“Despite the significant benefits of electronic medical records, healthcare organizations are not seeing the financial and clinical outcomes they had hoped for,” said Dr. Haugen, co-author of Beyond Implementation. “After investigating the outcomes of poor adoption and why physicians don’t get the full potential from EMR, we have identified one common thread. Too often, the primary focus is on go-live implementation when instead, this step should be the beginning of a sustained effort for the life of the application.”

About The Breakaway Group
The Breakaway Group helps healthcare providers quickly adopt new technology through a research-based method that uses innovative simulations and coaching to help improve patient care and safety. The firm’s unique approach to learning is based on the best-selling book “Breakaway” by CEO and Founder Charles Fred. For more information, visit www.thebreakawaygroup.com.

PT. HUENEME, CA–(Marketwire – September 9, 2010) –  Stellar Biotechnologies, Inc. (PINKSHEETS: SBOTF) (TSX-V: KLH) announces filing for patent protection of inventions related to its native Immunogenic (IMG) KLH technology platform and immune status monitoring product portfolio. KLH (keyhole limpet hemocyanin) is presently the most pharmaceutically important ICP (immune carrier protein) and IMG KLH is the most effective immune stimulant for use in cancer, viral and parasite vaccines; animal vaccines; and diagnostic products. Patent claims include pharmaceutical grade compositions of matter, processes for manufacture and methods of use in a wide range of therapies.

John Sundsmo, Ph.D., VP Research and Intellectual Property, said, “With filing of this patent application Stellar has achieved an important milestone on the road to becoming the preeminent world leader in development and manufacture of pharmaceutical grade immune carrier proteins. We are very pleased with the progress achieved by our scientists and what this patent application tangibly demonstrates.”

Corporate Website: www.StellarBiotechnologies.com
Stellar News at Marketwire: http://www.marketwire.com/mw/search.do?params=&grpSearch=C&companyid=70788

About Stellar Biotechnologies, Inc. (PINKSHEETS: SBOTF) (TSX-V: KLH) – (www.StellarBiotechnologies.com): is a world leader in sustainable manufacturing of pharmaceutical grade immune carrier proteins (ICP), particularly with regard to the present most important pharmaceutical protein in this class, KLH (Keyhole Limpet Hemocyanin). This ancient evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company’s securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

MADISON, WI–(Marketwire – September 9, 2010) – TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced, integrated radiation therapy solutions for cancer care, today announced that its technology will soon be used to treat cancer patients in Nottingham, England. The Nottingham Radiotherapy Centre will install the TomoTherapy^® Hi·Art^® treatment system in November as part of a service expansion and relocation. 

The TomoTherapy treatment system enables delivery of state-of-the-art CT image-guided intensity modulated radiotherapy (IG-IMRT), enabling the hospital to reinforce its leadership in high-quality, efficient cancer care for the people of the East Midlands of England.

The Nottingham Radiotherapy Centre serves a population of approximately 1 million and delivers 37,000 fractions of radiation therapy annually. The Centre provides complex external beam treatment including paediatric radiation therapy, intensity-modulated radiation therapy (IMRT), continuous hyperfractionation, and total body electron and photon radiation therapy. The centre is part of Nottingham University Hospitals National Health Service (NHS) Trust, which is one of the country’s largest teaching hospitals.

Russell Hart, Radiotherapy Service Manager of the Centre, states:

“Our multi-disciplinary team is thrilled to be introducing TomoTherapy technology. Benefits will include better access for our patients to what we believe is the best delivery system for complex image-guided, intensity-modulated radiation therapy (IG-IMRT). The new machine will also mean that there will be some patients for whom curative treatment will now be possible whereas in the past treatment would only have been offered on a palliative basis. A clear advantage of the TomoTherapy system is the rapid installation time. This will enable us to have the high technology available in a short space of time — much quicker than a conventional linear accelerator.

Here at Nottingham, in line with national policy, we believe that four-dimensional (4D) Adaptive Radiotherapy is the future standard of care for radiotherapy treatment, and that the TomoTherapy Hi·Art system is the most sophisticated and best system to achieve this objective. We believe our equipment strategy will provide us with a full range of treatment options for the population we serve, with the TomoTherapy system best able to deliver the most complex dose distributions.”

Commenting on the key role TomoTherapy technology is playing in a publicly funded health service, Julie Mead, Director and Clinical Advisor from Oncology Systems Limited, states:

“The oncology team at Nottingham put all equipment vendors through a rigorous clinical and technical public tender evaluation. They clearly concluded that the TomoTherapy platform would bring significant benefits to a centre that is reported as having one of the busiest patient throughput figures per treatment machine, in all of the UK. Already having a linac IMRT programme in place, the Nottingham Radiotherapy Centre also saw the improvement in treatment quality that TomoTherapy technology would bring, along with centre-wide efficiency gains from allocating advanced treatments to the unit. In difficult financial times, the TomoTherapy platform offers not only the best quality radiotherapy, but also the highest efficiency for advanced IG-IMRT. The NHS looks at cost-effectiveness as a key criterion. The TomoTherapy platform fits the bill.”

Reinforcing the efficiency requirements so critical to the publicly funded NHS, Nottingham’s Russell Hart adds:

“We treat between 35 to 50 patients per normal working day on our linear accelerators, depending on the complexity of the work being undertaken. We aim to maintain that throughput and utilise TomoTherapy technology to its maximum, by treating up to 35 patients per day. Other NHS TomoTherapy customer sites have demonstrated that this is possible in the UK, but of course this will be a tremendous achievement in Nottingham as we clearly expect that the treatments delivered on the TomoTherapy unit will have far higher quality and complexity than what is feasible on the linear accelerator it is replacing.”

TomoTherapy technology is developed and manufactured by TomoTherapy Inc., and is supplied in the UK by Oncology Systems Limited, based in Shrewsbury, England.

About Nottingham University Hospital
Nottingham City University Hospital NHS Trust (NUH) is one of England’s busiest and largest acute teaching trusts. It provides acute and specialist services to 2.5 million people within Nottingham and surrounding communities from the Queen’s Medical Centre and the City Hospital campuses. The hospital’s annual budget is in excess of £682 million of public sector funding, housing over 1,700 hospital beds and employing over 13,000 staff.

Nottingham is the only city in the country to secure three successful bids for prestigious biomedical research units. NUH is working with The University of Nottingham to help to translate research findings for stomach, bowel and liver disease, hearing and respiratory disease into better patient care.

About Oncology Systems Limited
Oncology Systems Limited (OSL) is a privately owned limited company based in Shrewsbury, England. OSL is an exclusive supplier of radiation therapy technology to the UK and Ireland. It distributes TomoTherapy^® cancer treatment technology to the UK’s NHS and private radiotherapy facilities, and to both public and private providers in the Republic of Ireland.

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy^® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art^® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD^™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile^™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

SCOTTSDALE, AZ–(Marketwire – September 9, 2010) – Top 10 women’s health site EmpowHER today launched what is expected to be the largest online movement for women’s health in the next year — the 1000Women campaign.

Expecting to engage 1,000 women who will each recruit another 1,000 women to participate in this classic pay-it-forward viral effort; the campaign’s goal is to get 1 million women to share their inspirational health stories with friends, family, and women they’ve never even met. Campaign participants can do this by creating profiles on 1000Women.com where they can: “tell a friend” about the campaign; share their own personal health and wellness story — including pictures and videos if they wish, or simply vote for another woman’s story that inspires them.

When 1 million women have engaged in the campaign, EmpowHER will donate $50,000 toward women’s health research.

“Participants in this campaign are not required to spend a penny. Every time a new woman signs up to share a story, vote for a story, or share the campaign with others, money will be donated by EmpowHER to fund women’s health research,” said Thom Brodeur, Chief Marketing Officer for EmpowHER and campaign architect. “Our challenge to women is simple. Open your hearts, log onto the website, and pass it along. We’ll open our wallet and do the rest. We’re partnering with women to improve their health and change their lives, and we’re honored to play a role.”

The majority of campaign funds will be donated to HealthyWomen, the nation’s leading nonprofit health information source for women. For more than 20 years, HealthyWomen has been committed to improving women’s health through public education campaigns grounded in research among women nationwide.

“Studies show that when women share their health issues with other women, their state of mind improves, sometimes even having positive effects on their overall health,” said Jay K. Harness, MD, a member of EmpowHER’s Medical Advisory Board, President of Breast Surgery International and breast surgeon in Orange County, Calif. “For example, a recent report from the California HealthCare Foundation reported that when patients managing the same chronic condition share observations with each other, their collective wisdom can yield clinical insights well beyond the understanding of any single patient or physician.”

Dr. Harness, past president of the American Society of Breast Surgeons, goes on to say, “Studies have found that cancer patients who were isolated and lacked social interaction had greater tumor growth and worse prognosis. We firmly believe that loneliness and isolation can have a significant impact on a patient’s long-term battle with a disease.” Dr. Harness concluded that online communities are a great resource for patients to share and connect, but are not a substitution for oversight and guidance from a patient’s medical team.

“Women need to advocate for themselves and each other by calling for more gender-specific health research,” said Michelle King Robson, Founder, Chairperson and CEO of EmpowHER. “Much of the world’s health-related research remains male dominated, signaling there is still much to learn about women’s unique health conditions and the specific effects of procedures, drugs and diagnostics on women. This campaign was created to give women a voice in their own health, and to provide financial support to organizations dedicated to advancing women’s health research and advocacy.”

King Robson has witnessed this trend first-hand. Her site, launched just 24 months ago, reaches nearly 1.2 million unique visitors and viewers every month from women sharing their most intimate health conditions and then connecting with others for support. “I started this site after I experienced my own health nightmare and began telling my story. What has occurred has been a firestorm of other women who have found solace and better health by sharing on EmpowHER.com. We now want to take this to a new level of connectivity for all women around the globe by giving them a voice in their health through this campaign.”

To participate in the 1000Women Campaign, please visit www.1000Women.com.

About EmpowHER
EmpowHER is an award-winning health media company for women. The Company’s website provides visitors access to one of the largest women’s health and wellness content libraries on the web, as well as the largest online community of women discussing their health and wellness issues. EmpowHER promotes a “24 Hour Promise” to its visitors, who can come to the site, ask any health question and receive a response within 24 hours. Health care marketers rely on EmpowHER for reaching the most influential health and wellness buying audience on the Internet — women. Millions of women visit EmpowHER.com every year, making it one of the largest and fastest-growing resources dedicated exclusively to women’s health and wellness. For more, visit www.EmpowHER.com.

About HealthyWomen
HealthyWomen (HW) is the nation’s leading independent health information source for women. For more than 20 years, women have been coming to the HW for answers to their most pressing and personal health care questions. HW provides health information through a wide array of online content and print publications that are original, objective and reviewed and approved by medical experts. Its website, www.HealthyWomen.org®, was recognized by ForbesWoman as one of the “Top 100 Websites for Women” and was named the top women’s health website by Dr. Mehmet Oz in O, The Oprah Magazine and by Good Housekeeping magazine. To learn more, visit www.HealthyWomen.org.

id=”nav_links”>

CHICAGO, IL–(Marketwire – September 8, 2010) –  Graham Czach‘s wild creativity and unique versatile sound have earned the Windy City native a nomination for The Deli Chicago’s Artist of the Month. Fans can vote online through September 15 by clicking http://chicago.thedelimagazine.com/snacks.

The socially conscious rocker (www.grahamczach.com) is also teaming up with Planned Parenthood of Illinois (PPIL) to celebrate the official release of his independent debut album Lucid on Friday, October 15 at Martyrs (3855 North Lincoln Ave.) in Chicago. The show begins at 9:30 p.m. Tickets are $12 and may be purchased at www.martyrslive.com or at the door.

With a Chicago Music Award under his belt, the versatile singer/songwriter and multi-instrumentalist will bring his modern and progressive rock sensibilities to life performing with the album’s original band members: drummer Kris Myers (Umphrey’s McGee), keyboardist Matt Nelson (Lupe Fiasco, Matthew Santos), guitarist Chris Siebold (Howard Levy, Kick the Cat) and bassist Graham Burris (Lupe Fiasco, Matthew Santos).

Czach — whose album includes a powerful song about abortion rights titled “Choice” — is donating a portion of sales generated from the event to PPIL. PPIL’s 17 health centers throughout the state deliver comprehensive reproductive health care services, sex education, and sexual health information to more than 60,000 women, men, and teens each year.

In addition to Planned Parenthood of Illinois, a portion of the proceeds from Lucid is being donated to other non-profit organizations including Greenpeace, the American Cancer Society and the Art of Living Foundation.

As Lucid sheds light on these important social issues and more, Czach draws on a fascinating, diverse musical background — which includes his work with Chicago Afrobeat Project — to create musical landscapes as compelling as the lyrics. He was recently interviewed by Skope Magazine‘s editor Mike Friedman and by Lisa Smith of The Blend Magazine for their Take Action Party surrounding his earth-friendly messages.

Tapping into his childhood where Led Zeppelin, The Beatles and Crosby, Stills, Nash & Young were practically a religion, and later influences like Pink Floyd, Red Hot Chili Peppers, The Mars Volta and Jimi Hendrix, he infuses hard rocking, sometimes unusually metered grooves to four (and more) part vocal harmonies, beautiful acoustic melodies and vibrant unfolding string arrangements.

Click here to see all recent news from this company

MUNDELEIN, IL–(Marketwire – September 8, 2010) –  A little over a year after Medline Industries, Inc., the largest privately held manufacturer and distributor of healthcare supplies in the U.S., completed and opened its new environmentally conscious service facility center in Dubuque, Iowa, the building officially received Leadership in Energy and Environmental Design (LEED) silver certification.

LEED is an internationally recognized, third party validation system of certification for many buildings. It measures and evaluates design, construction, operation and maintenance solutions. LEED is generally viewed as a trusted benchmark for a building’s impact on the environment.

In order to receive this certification, Medline applied and the building was then evaluated by LEED, who allocated points based on preset green criteria — focusing on energy efficiency and CO₂ reduction. There are seven areas on which LEED evaluated the service facility: sustainability of the site, water efficiency, energy and atmosphere, materials and resources, indoor environmental quality, location and linkages, awareness and education, innovation in design and regional priority. To achieve silver certification, the second highest certification category, the service facility was awarded points that placed them in the 60-79 point range out of a 100-base point system. 

“The building was constructed with the environment and LEED certification in mind,” said Robert Abrams, the Corporate Director who oversaw the project. “Some of the green aspects of the 66,000-square-foot facility are daylight harvesting energy-efficient lighting, solar-tracking skylights, technologically advanced building insulation materials, tankless hot water heaters and a geothermal heating system.”

The installation of these and other green technologies resulted in an electrical use reduction of 320,565 kWh, which avoids more than 230 metric tons of carbon dioxide. This is equivalent to removing the CO₂ emissions from 26,131 gallons of gasoline consumed or 535 barrels of oil consumed. All of this gathered points for certification as well as small things, such as close parking for a Prius, cubical walls made with recycled fabric that traveled less than 500 miles from their manufacturer and energy efficient trash management. 

“I think it demonstrates Medline’s commitment to the environment as a company, and it was important for our customers,” Abrams said. “We’re being asked more and more what we’re doing to reduce our carbon footprint.”

About Medline Industries, Inc. 
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended-care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, Ill., Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest-growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and healthcare systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities and on-staff clinicians.

BETHESDA, MD–(Marketwire – September 8, 2010) –  Coventry Health Care, Inc. (NYSE: CVH) announced today that John Stelben, Interim Chief Financial Officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference in New York, New York, at 1:00 p.m. ET on Monday, September 13, 2010. 

The public may access a live webcast of the presentation on the Investor Relations page of Coventry’s website at www.coventryhealthcare.com. A replay of the presentation will be available at the same website following the presentation until Monday, September 20, 2010.

Coventry Health Care (www.coventryhealthcare.com) is a diversified national managed healthcare company based in Bethesda, Maryland, operating health plans, insurance companies, network rental and workers’ compensation services companies. Coventry provides a full range of risk and fee-based managed care products and services to a broad cross section of individuals, employer and government-funded groups, government agencies, and other insurance carriers and administrators.

RALEIGH, NC–(Marketwire – September 8, 2010) –  InoLife Technologies, Inc. (OTCBB: INOL), a service based healthcare products development, integration and marketing Company, is extremely pleased that their recently presented Cytochrome P450 2C1 test to determine a person’s ability to metabolize Plavix is immediately available to the medical industry which includes physicians, hospitals, medical clinics, and pharmacies. Physicians are currently placing orders on a daily basis and are incorporating the Cytochrome P450 2C1 Plavix Metabolizing test into their patients health programs. 

InoLife’s Cytochrome P450 2C1 test is currently being used to identify how a patient’s genetics may affect the body’s response to Plavix (Clopidogrel). The test is available through the medical community only including physicians, hospitals, and medical clinics. This test is not available for sale to the general public.

According to the FDA in a press release dated March 12^th, 2010 it is estimated that 2 percent to 14 percent of the U.S. population are poor metabolizers of certain medications. In 2009 the Federal Drug Administration approved wording on the drug label encouraging genetic testing for DNA variants based on specific risks. It is important to note that this drug metabolism test is not all-inclusive and is for the physician’s guidance only.

InoLife has incorporated the EasiCollect™ System, which combines an optimized foam collection surface with an FTA card for collection of buccal cells and preservation of DNA. InoLife prides itself in providing the EasiCollect™ System that adheres to the strict guidelines of the Clinical Laboratory Improvement Amendments (CLIA) that monitors approximately 200,000 laboratory entities. The Center for Medicare & Medicaid Services regulates all laboratory testing (except research) performed on humans in the U.S. through CLIA.

About InoLife Technologies, Inc.
InoLife is poised to become one of the premier U.S. marketers of state-of-the-art DNA-based test products. Positioned for growth and success in a burgeoning market, InoLife Technologies, www.inolifetech.com, is primarily focused on products, services and solutions that will enable state-of-the-art healthcare for today and the future for a diverse base of customers and end users. The Company’s mission is to identify, develop, integrate and bring to market innovative healthcare-based products and services that provide timely and practical solutions. The primary products and services that InoLife is currently addressing focuses upon those specific products and services that provide key solutions through the innovative use of specific DNA testing and Genetic analysis systems.

The principal customers of InoLife’s products and services are healthcare providers, physicians, practitioners, hospitals and outpatient facilities. InoLife will be marketing and distributing its products through traditional distribution channels. Additionally InoLife has developed certain products that can be sold directly to consumers and has created specific programs to reach those customers including e-commerce, direct sales, healthcare providers, pharmacies, distributors, retail sellers and specialty retailers.

(Plavix is a trademark of Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership.)

Forward-Looking Statements
Safe Harbor Statement under the Private securities Litigation Reform Act of 1995: The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements including, but not limited to, certain delays beyond the Company’s control with respect to market acceptance of new technologies, products and services, delays in testing and evaluation of products and services, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission.

VANCOUVER, BRITISH COLUMBIA–(Marketwire – Sept. 8, 2010) – ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCQB:APCSF) (the “Company”) is pleased to announce that it has closed the private placement announced July 27^th, 2010. A total of 3,275,000 Units of the Company were issued at a price of $0.10 per Unit for gross proceeds of $327,500. All securities issued with respect to the private placement will be subject to a hold period expiring on January 8, 2011 in accordance with the policies of the TSX Venture Exchange and applicable Canadian securities laws. 

Each Unit consists of one common share of ALDA and one non-transferable share purchase warrant entitling the holder to acquire one additional common share of ALDA at a price of $0.20 per common share for a period of two (2) years from the date of the issuance of the purchase warrant with a forced exercise provision attached to each warrant commencing on the day following the expiry of any applicable hold period on the underlying Common Share, stating that if, for ten consecutive trading days, the closing price of the listed shares of the Company exceeds $0.40 then the exercise period of the warrants will be reduced to a period of 10 days following such trading days. Net proceeds from the offering will be used for working capital.

The Company paid finders’ fees of $2,250 (5% of the gross proceeds of $45,000) to certain registrants with respect to the offering.

Insiders of ALDA subscribed for 677,500 Units on the same terms as arm’s length investors, constituting a related party transaction pursuant to Multilateral Instrument 61-101 and TSX Venture Exchange Policy 5.9. Such Insider participation was exempt from the requirement to obtain an independent valuation pursuant to Section 5.5(b) of MI 61-101 and the requirement to obtain minority shareholder approval pursuant to Section 5.7(1)(b) of MI 61-101.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T³6^® technology. The company trades on the TSX Venture Exchange under the symbol APH and on the OTCQB under the symbol APCSF. The Company was the Official Supplier to the Vancouver 2010 Olympic Winter Games and the Vancouver 2010 Paralympic Winter Games and is the Official Supplier to the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant cleaning products. The Company was also selected as one of the TSX Venture 50 companies in the Technology and Life Sciences sector for 2010.

Terrance G. Owen, Ph.D., MBA
President & CEO
ALDA Pharmaceuticals Corp.
www.aldacorp.com

The Units, common shares, warrants and the common shares issuable upon exercise of the warrants have not been registered under the United States Securities Act of 1933 (the “Act”) and may not be offered or sold absent registration under the Act or an applicable exemption from the registration requirements thereof. This news release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction or an exemption therefrom.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as “outlook”, “will”, “could”, “would”, “might”, “remains”, “to be”, “plans”, “believes”, “may”, “expects”, “intends”, “anticipates”, “estimate”, “future”, “plan”, “positioned”, “potential”, “project”, “remain”, “scheduled”, “set to”, “subject to”, “upcoming”, and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.